The authors would like to thank Dr.ssa Silvia Graziano for technical help.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: The study was supported by the Presidency of the Ministers Council, Department of Antidrug Policy.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
1. Regulation (EU) no 1307/2013 of the European parliament and of the council. Establishing rules for direct payments to farmers under support schemes within the framework of the commonagricultural policy and repealing Council Regulation (EC) No 637/2008 and Council Regulation (EC) No 73/2009. . Accessed: 2020-12-01.Search in Google Scholar
2. Commission Delegated Regulation (EU) 2017/1155 of 15 February 2017. . Accessed: 2019-30-12.Search in Google Scholar
3. Disposizioni per la promozione della coltivazione e della filiera agroindustriale della canapa. LEGGE 2 dicembre 2016, n. 242. . Accessed: 2020-12-01.Search in Google Scholar
4. Pacifici R, Pichini S, Pellegrini M, Tittarelli R, Pantano F, Mannocchi G, et al. Determination of cannabinoids in oral fluid and urine of “light cannabis” consumers: a pilot study. Clin Chem Lab Med 2018;57:238–43.Search in Google Scholar
5. Pacifici R, Pichini S, Pellegrini M, Rotolo MC, Giorgetti R, Tagliabracci A, et al. THC and CBD concentrations in blood, oral fluid and urine following a single and repeated administration of “light cannabis”. Clin Chem Lab Med 2019. DOI: 10.1515/cclm-2019-0119. [Epub ahead of print].Search in Google Scholar
6. Pichini S, Mannocchi G, Berretta P, Zaami S, Pirani F, Pacifici R, et al. Δ9-tetrahydrocannabinol and cannabidiol time courses in the sera of “light cannabis” smokers: discriminating light cannabis use from illegal and medical cannabis use. Ther Drug Monit 2020;42:151–56.Search in Google Scholar
7. Mannucci C, Navarra M, Calapai F, Spagnolo EV, Busardò FP, Cas RD, et al. Neurological aspects of medical use of cannabidiol. CNS Neurol Disord Drug Targets 2017;16:541–53.Search in Google Scholar
8. Berman P, Futoran K, Lewitus GM, Mukha D, Benami M, Shlomi T, et al. A new ESI-LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis. Sci Rep 2018;8:14280.Search in Google Scholar
9. Pacifici R, Marchei E, Salvatore F, Guandalini L, Busardò FP, Pichini S. Evaluation of cannabinoids concentration and stability in standardized preparations of cannabis tea and cannabis oil by ultra-high performance liquid chromatography tandem mass spectrometry. Clin Chem Lab Med 2017;55:1555–63.Search in Google Scholar
10. Dussy FE, Hamberg C, Luginbühl M, Schwerzmann T, Briellmann TA. Isolation of Δ9-THCA-A from hemp and analytical aspects concerning the determination of Δ9-THC in cannabis products. Forensic Sci Int 2005;149:3–10.Search in Google Scholar
11. Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò FP. Cannabidiol adverse effects and toxicity. Curr Neuropharmacol 2019;17:974–89.Search in Google Scholar
©2020 Walter de Gruyter GmbH, Berlin/Boston